Evidence map›Paper›PMID 29953487›Full record

ArticlePloS one2018

Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene.

Poorva Sandlesh, Thierry Juang, Alfiya Safina, Michael J Higgins, Katerina V Gurova

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ERInternational journal of molecular sciences · 2022
    Article
  5. Generation and Comparative Analysis of anNature cardiovascular research · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A neuroscientist's guide to transgenic mice and other genetic tools.Neuroscience and biobehavioral reviews · 2020
    Review
  11. Article
  12. Structure and function of the histone chaperone FACT - Resolving FACTual issues.Biochimica et biophysica acta. Gene regulatory mechanisms · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Poorva SandleshDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Thierry JuangDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Alfiya SafinaDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Michael J HigginsDepartment of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Katerina V GurovaDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.ORCID 0000-0001-9189-0712
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Modulation of cancer specific transcriptional factors with small moleculesR01CA197967 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GUROVA, KATERINA V · 2015 to 2019
$2.0M
Safety and anti-cancer efficacy of FACT inactivation in miceR21CA198395 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GUROVA, KATERINA V · 2015 to 2016
$420k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA197967NCI NIH HHS R21 CA198395
6 · The paper itself

Abstract

FAcilitates Chromatin Transcription (FACT) is a complex of SSRP1 and SPT16 that is involved in chromatin remodeling during transcription, replication, and DNA repair. FACT has been mostly studied in cell-free or single cell model systems because general FACT knockout (KO) is embryonically lethal (E3.5). FACT levels are limited to the early stages of development and stem cell niches of adult tissues. FACT is upregulated in poorly differentiated aggressive tumors. Importantly, FACT inhibition (RNAi) is lethal for tumors but not normal cells, making FACT a lucrative target for anticancer therapy. To develop a better understanding of FACT function in the context of the mammalian organism under normal physiological conditions and in disease, we aimed to generate a conditional FACT KO mouse model. Because SPT16 stability is dependent on the SSRP1-SPT16 association and the presence of SSRP1 mRNA, we targeted the Ssrp1 gene using a CreERT2- LoxP approach to generate the FACT KO model. Here, we highlight the limitations of the CreERT2-LoxP (Rosa26) system that we encountered during the generation of this model. In vitro studies showed an inefficient excision rate of ectopically expressed CreERT2 (retroviral CreERT2) in fibroblasts with homozygous floxed Ssrp1. In vitro and in vivo studies showed that the excision efficiency could only be increased with germline expression of two alleles of Rosa26CreERT2. The expression of one germline Rosa26CreERT2 allele led to the incomplete excision of Ssrp1. The limited efficiency of the CreERT2-LoxP system may be sufficient for studies involving the deletion of genes that interfere with cell growth or viability due to the positive selection of the phenotype. However, it may not be sufficient for studies that involve the deletion of genes supporting growth, or those crucial for development. Although CreERT2-LoxP is broadly used, it has limitations that have not been widely discussed. This paper aims to encourage such discussions.

Indexed as

IntegrasesMultiprotein ComplexesTranscription FactorsAnimalsDNA-Binding ProteinsGene Knockout TechniquesHigh Mobility Group ProteinsMiceMice, KnockoutCre recombinaseDNA-Binding ProteinsHigh Mobility Group ProteinsIntegrasesMultiprotein ComplexesSsrp1 protein, mouseSupt16 protein, mouseTranscription Factors

Identifiers

PMID29953487
PMCPMC6023160
OpenAlexW2810697443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.